Multicohort genomic-transcriptomic analyses uncover genetic drivers and therapeutic vulnerabilities in prostate cancer

Prostate cancer is a disease that affects millions of men worldwide, and while doctors have become very good at spotting it, understanding exactly why it starts and how it grows remains a complex puzzle. For decades, scientists have known that a person's genetic code plays a massive role in their risk of developing the disease. Imagine the human genome as a vast library of instructions; researchers have found hundreds of specific typos in these instructions that make some men more likely to get prostate cancer than others. However, most of these typos sit in the quiet, empty spaces between the actual genes, like footnotes in a book that don't seem to say anything at first. Figuring out what these footnotes actually mean is the key to understanding the disease. Furthermore, for a long time, the maps scientists used to read these genetic footnotes were drawn almost entirely from people of European ancestry. This created a blind spot, leaving the genetic stories of men from other parts of the world, particularly in East Asia, largely unread and unexplained.

A team of researchers from China and other institutions has now filled in a significant part of that missing map. They turned their attention to a large group of Chinese men with prostate cancer, analyzing the genetic code and the active gene messages in both their tumors and their healthy tissue. By comparing these two states side-by-side, they were able to see which genetic footnotes were active in healthy men and which ones changed as the cancer grew. This approach allowed them to identify specific genes that are driven by these inherited risk factors. Among the many genes they found, one stood out as a major player: a gene called UHRF1BP1. The researchers discovered that this gene acts like a volume knob for a critical signaling pathway that drives prostate cancer growth. When this gene is turned up high, it helps the cancer cells grow faster and become resistant to standard treatments.

The study began by looking at the genetic data of 134 Chinese men who had undergone surgery for prostate cancer. For each man, the team had access to the DNA from his tumor and the DNA from the healthy prostate tissue right next to it. They also had the active gene messages, or transcripts, from both tissues. This pairing was crucial because it let them see how the genetic instructions were being read differently in the cancer compared to the healthy tissue. They found that while many genetic influences on gene activity remained the same whether the tissue was healthy or cancerous, a large number of influences changed specifically when the tissue became malignant. Some genetic footnotes that were silent in healthy tissue suddenly became loud and active in the tumor, while others that were active in healthy tissue went quiet. This revealed that the genetic rules governing the prostate are not static; they are rewritten as the disease progresses.

To make sense of these findings, the researchers compared their new data from Chinese men with existing data from large studies of European men. They found that the genetic footnotes that mattered most for prostate cancer risk in East Asian men were often different from those that mattered for European men. If scientists had only looked at the European data, they would have missed many of the important genetic drivers in the Chinese population. This confirmed that to truly understand prostate cancer, researchers must look at the specific genetic backgrounds of different populations. By combining their new data with genetic risk maps from around the world, the team narrowed down a long list of potential culprits to a smaller group of 98 genes that were most likely to be the true drivers of the disease.

From this list, one gene, UHRF1BP1, emerged as the most promising target. In the patients' tumors, this gene was turned on much higher than in their healthy tissue. The researchers then took this finding out of the computer and into the laboratory to see what the gene actually did. They used prostate cancer cells in a dish and turned off the UHRF1BP1 gene. Without this gene, the cancer cells stopped growing as fast, they lost their ability to move, and they struggled to form new colonies. When they tested this in mice, the tumors that lacked the gene grew much slower and were less likely to spread to the lungs. This proved that UHRF1BP1 was not just a marker of the disease, but an active engine driving it forward.

The next question was how this gene worked. The researchers found that UHRF1BP1 helps stabilize the messages for the androgen receptor, a protein that prostate cancer cells rely on to grow. Think of the androgen receptor as the fuel pump for the cancer cell; if the fuel pump is broken, the cell cannot grow. UHRF1BP1 acts like a protective cover for the instructions that build this fuel pump, keeping them from falling apart. It does this by teaming up with another protein called DDX1, which acts like a molecular glue to hold the instructions together. When UHRF1BP1 is present, the fuel pump instructions stay stable, and the cancer keeps growing. When UHRF1BP1 is removed, the instructions fall apart, the fuel pump breaks down, and the cancer slows its growth.

This mechanism has a direct impact on how patients respond to treatment. The standard treatment for advanced prostate cancer is a drug called enzalutamide, which tries to block the fuel pump. However, many patients eventually stop responding to this drug because their cancer cells find ways to keep the pump running, often by making a shortened version of the fuel pump that the drug cannot stop. The researchers found that UHRF1BP1 helps keep these shortened, drug-resistant versions of the fuel pump stable. When they blocked UHRF1BP1 in the lab, the cancer cells became much more sensitive to enzalutamide. In mice, combining the removal of UHRF1BP1 with the standard drug stopped the tumors from growing much more effectively than the drug alone.

The researchers also built a public database to share all the genetic and gene activity maps they created. This tool allows other scientists to search for specific genetic changes and see how they relate to gene activity and patient outcomes. By making this data available, they hope to help other researchers find new targets for treatment and better understand the disease in different populations. The study concludes that by looking at the genetic stories of diverse groups of people, scientists can uncover new biological mechanisms that were previously hidden. The discovery of UHRF1BP1 as a key regulator of prostate cancer growth offers a new path forward, suggesting that targeting this gene could help overcome resistance to current treatments and improve outcomes for men with aggressive disease.